Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background Patients and clinicians have begun to recognize the advantages and disadvantages of buprenorphine relative to methadone, but factors that influence choices between these two medications remain unclear. For example, we know little about how patients’ preferences and previous experiences influence treatment decisions. Understanding these issues may enhance treatment engagement and retention. Methods Adults with opioid dependence (n = 283) were recruited from two integrated health systems to participate in interviews focused on prior experiences with treatment for opioid dependence, knowledge of medication options, preferences for treatment, and experiences with treatment for chronic pain in the context of problems with opioids. Interviews were audio-recorded, transcribed verbatim, and coded using Atlas.ti. Results Our analysis revealed seven areas of consideration for opioid agonist treatment decision-making: 1) awareness of treatment options; 2) expectations and goals for duration of treatment and abstinence; 3) prior experience with buprenorphine or methadone; 4) need for accountability and structured support; 5) preference to avoid methadone clinics or associated stigma; 6) fear of continued addiction and perceived difficulty of withdrawal; and 7) pain control. Conclusion The availability of medication options increases the need for clear communication between clinicians and patients, for additional patient education about these medications, and for collaboration and patient influence over choices in treatment decision-making. Our results suggest that access to both methadone and buprenorphine will increase treatment options and patient choice and may enhance treatment adherence and outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The theory of planned behavior
Ajzen, I. (1991) · Organizational Behavior and Human Decision Processes · doi:10.1016/0749-5978(91)90020-t · Cited by 90,587
The Discovery of Grounded Theory; Strategies for Qualitative Research
Glaser, B. G., Strauss, A. L., & Strutzel, E. (1968) · Nursing Research · doi:10.1097/00006199-196807000-00014 · Cited by 39,449
Drug Dependence, a Chronic Medical Illness
McLellan, A. T., Lewis, D. C., O'Brien, C. P., & Kleber, H. D. (2000) · JAMA · doi:10.1001/jama.284.13.1689 · Cited by 2,622 · cited 2×
“Discussions about the chronic and relapsing course of substance dependence (McLellan et al., 2000) and patients’ ongoing vulnerability to opioids are valuable because they may help patients to appreciate and Yarborough et al.”
BackgroundLégaré, F., Ratté, S., Gravel, K., & Graham, I. D. (2008) · Patient Education and Counseling · doi:10.1016/j.pec.2008.07.018 · Cited by 1,321 · cited 2×
“Barriers common to shared decision-making in other domains, such as lack of time (Legare et al., 2008) or the inherent tension created when patient goals contradict evidence-based treatment recommendations (e.g., preference for shorter treatment duration) may also be factors in opioid agonist…”
BackgroundJoosten, E. A. G., DeFuentes-Merillas, L., de Weert, G. H., Sensky, T., van der Staak, C. P. F., & de Jong, C. A. J. (2008) · Psychotherapy and Psychosomatics · doi:10.1159/000126073 · Cited by 1,135 · cited 1×
“In the context of chronic illnesses that require long-term treatment decisions, like chronic pain and opioid dependence, shared decision-making is effective for reaching treatment agreement (Joosten et al., 2008).”
BackgroundBuprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Kimber, J., Breen, C., & Davoli, M. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub3 · Cited by 501
Maintenance Medication for Opiate Addiction: The Foundation of Recovery
Bart, G. (2012) · Journal of Addictive Diseases · doi:10.1080/10550887.2012.694598 · Cited by 461 · cited 3×
“In the United States, methadone is the opioid agonist most studied and most frequently used for agonist therapy of opioid use disorders (Substance Abuse and Mental Health Services Administration (SAMHSA), 2014), and there is ample, longstanding evidence of its effectiveness (Bart, 2012; Mattick et al., 2008).”
BackgroundNeumann, A. M., Blondell, R. D., Jaanimägi, U., Giambrone, A. K., Homish, G. G., Lozano, J. R., Kowalik, U., & Azadfard, M. (2013) · Journal of Addictive Diseases · doi:10.1080/10550887.2012.759872 · Cited by 90 · cited 1×
“Finally, as others have also noted, we found that treating pain with co-occurring substance use remains a challenge both for patients and clinicians (Neumann et al., 2013; Weiss et al., 2014).”
Background
Cited by
Stigma as a fundamental hindrance to the United States opioid overdose crisis response
Tsai, A. C., Kiang, M. V., Barnett, M. L., Beletsky, L., Keyes, K. M., McGinty, E. E., Smith, L. R., Strathdee, S. A., Wakeman, S. E., & Venkataramani, A. S. (2019) · PLOS Medicine · doi:10.1371/journal.pmed.1002969 · Cited by 437
Stress and opioid use disorder: A systematic review
MacLean, R. R., Armstrong, J. L., & Sofuoglu, M. (2019) · Addictive Behaviors · doi:10.1016/j.addbeh.2019.05.034 · Cited by 43
Price, C. J., Merrill, J. O., McCarty, R. L., Pike, K. C., & Tsui, J. I. (2020) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2019.05.013 · Cited by 33
Methadone and Suboxone® mentions on Twitter: Thematic and Sentiment Analysis (Preprint)
Chenworth, M., Perrone, J., Hogg, W., & Sarker, A. (2020) · doi:10.2196/preprints.19700
Metadata
- Authors
- Yarborough, B. J. H., Stumbo, S. P., McCarty, D., Mertens, J., Weisner, C., & Green, C. A.
- Venue
- Drug and Alcohol Dependence
- Publisher
- Elsevier BV
- Published
- 2016-03
- Volume
- 160
- Pages
- 112-118
- ISSN
- 0376-8716 (ISSN-L)
- OpenAlex
- W2224997939
- Cited by
- 157
- References
- 8
- FWCI
- 12.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis. https://app.cochat.ai/papers/10.1016/j.drugalcdep.2015.12.031
- The paper
- Yarborough, B. J. H., Stumbo, S. P., McCarty, D., Mertens, J., Weisner, C., & Green, C. A. (2016). Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis. Drug and Alcohol Dependence. https://doi.org/10.1016/j.drugalcdep.2015.12.031
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.